🔍 Companies struggle with fragmented data, impacting efficiency and compliance.
🚀 Executives acknowledge spending extensive time on data cleaning rather than innovation.
📈 Forward-thinking firms are adopting advanced data platforms to improve operations and regulatory readiness.
⏰ Rethinking data infrastructure is crucial for future success as regulatory demands increase.
Introduction:
The article discusses the significant challenges posed by a scientific data crisis in the biopharmaceutical industry, particularly affecting Chemistry, Manufacturing, and Controls (CMC) operations. The urgency to modernize data infrastructure is emphasized as companies accelerate towards AI-driven drug development while facing inefficiencies and regulatory pressures related to data management.
- The scientific data crisis is hindering the overall efficiency and effectiveness of CMC processes crucial for drug development.
- Companies are wasting significant time on manual data transcription due to fragmented data systems, with estimates of up to 100 hours lost weekly.
- CMC data presents unique challenges because it must integrate diverse instrument types, adhere to regulatory requirements, and accommodate document-centric workflows.
- Upcoming regulatory mandates for electronic CMC submissions will increase the burden on firms lacking a robust data infrastructure.
- Adopting purpose-built scientific data platforms can enhance manufacturing operations and accelerate timelines, ultimately improving regulatory compliance and scientific intelligence.
Conclusion:
The article highlights the pressing need for biopharmaceutical manufacturers to urgently address their data infrastructure to overcome inefficiencies and regulatory challenges in CMC operations. Companies that invest in modern scientific data platforms are likely to achieve notable advantages in manufacturing efficiency, compliance, and overall process knowledge, positioning themselves for better success in a competitive landscape.
